Emmaus Life Sciences, INC. (EMMA) — SEC Filings

Q: What are the key financial highlights for Emmaus Life Sciences, INC.?

Key financial highlights for Emmaus Life Sciences, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Emmaus Life Sciences, INC.?

Key executives at Emmaus Life Sciences, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Emmaus Life Sciences, INC. stock?

Risk factors for Emmaus Life Sciences, INC. (EMMA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Emmaus Life Sciences, INC.?

Forward-looking statements and predictions from Emmaus Life Sciences, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Emmaus Life Sciences, INC.. Recent 8-K filing on Mar 31, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Emmaus Life Sciences, INC. on SEC EDGAR

Overview

Emmaus Life Sciences, INC. (EMMA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: Emmaus Life Sciences, Inc. filed an 8-K on March 31, 2026, reporting its financial results and condition as of March 30, 2026. The filing includes a press release dated March 30, 2026, and various financial exhibits in XBRL format.

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 2 bearish, 24 neutral. The dominant filing sentiment for Emmaus Life Sciences, INC. is neutral.

Filing Type Overview

Emmaus Life Sciences, INC. (EMMA) has filed 19 8-K, 5 10-Q, 2 10-K with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (26)

Emmaus Life Sciences Files 8-K with Financial Results — 8-K · Mar 31, 2026 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on March 31, 2026, reporting its financial results and condition as of March 30, 2026. The filing includes a press relea
8-K Filing — 8-K · Dec 31, 2025
8-K Filing — 8-K · Dec 22, 2025
Emmaus Life Sciences Files 8-K on Director/Officer Changes — 8-K · Dec 19, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on December 19, 2025, reporting on events as of December 15, 2025. The filing covers the departure of directors, electio
8-K Filing — 8-K · Nov 14, 2025
Emmaus Life Sciences' Revenue Plummets 35% Amid Mounting Losses — 10-Q · Nov 14, 2025 Risk: high
Emmaus Life Sciences, Inc. (EMMA) reported a significant decline in net revenues for the nine months ended September 30, 2025, falling to $8.601 million from $1
Emmaus Life Sciences Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
Emmaus Revenues Plunge, Going Concern Doubts Persist Amidst Debt Load — 10-Q · Aug 14, 2025 Risk: high
Emmaus Life Sciences, Inc. (EMMA) reported a significant decline in net revenues for the three and six months ended June 30, 2025. Net revenues decreased by 47.
Emmaus Life Sciences Files 8-K with Officer and Director Updates — 8-K · Jul 1, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on June 30, 2025, reporting changes in its board of directors and executive officers, as well as updates to compensatory
Emmaus Life Sciences Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Emmaus Life Sciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial
Emmaus Life Sciences Changes Independent Auditor — 8-K · May 6, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on May 6, 2025, reporting a change in its certifying accountant. The company previously engaged WithumSmith+Brown, PC, b
Emmaus Life Sciences Files 8-K on Financials — 8-K · Apr 14, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on April 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial st
Emmaus Life Sciences Files 2024 10-K — 10-K · Apr 14, 2025 Risk: medium
Emmaus Life Sciences, Inc. filed its 2024 10-K on April 14, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as MYnd Ana
Emmaus Life Sciences Files 8-K on Financials — 8-K · Nov 19, 2024 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on November 19, 2024, reporting on its results of operations and financial condition, as well as financial statements an
Emmaus Life Sciences Files Q3 2024 10-Q — 10-Q · Nov 19, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as MYnd Analytics, Inc., reported on its financi
Emmaus Life Sciences Board Changes and Officer Compensation — 8-K · Nov 6, 2024 Risk: medium
Emmaus Life Sciences, Inc. announced on November 4, 2024, a change in its board of directors. Specifically, Dr. Y. K. Kim has been appointed as a new director,
Emmaus Life Sciences Appoints New Auditor — 8-K · Oct 25, 2024 Risk: medium
Emmaus Life Sciences, Inc. announced on October 22, 2024, that it has appointed a new independent registered public accounting firm, CohnReznick LLP, to audit i
Emmaus Life Sciences Files 8-K on Officer/Director Changes — 8-K · Oct 4, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on October 4, 2024, reporting on events as of September 30, 2024. The filing covers the departure of directors or certai
Emmaus Life Sciences Changes Auditors — 8-K · Sep 10, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on September 5, 2024, reporting changes in its certifying accountant. The company has dismissed its previous independent
Emmaus Life Sciences 10-Q: Financials and Derivatives — 10-Q · Sep 10, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported a net loss on investment in a convertible bond and a gain/l
Emmaus Life Sciences Files 8-K on Director/Officer Changes — 8-K · Jul 17, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed an 8-K on July 17, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compe
Emmaus Life Sciences Files 8-K on Financials — 8-K · Jul 3, 2024 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on July 3, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
Emmaus Life Sciences Files 2023 10-K — 10-K · Jul 3, 2024 Risk: medium
Emmaus Life Sciences, Inc. filed its 2023 10-K on July 3, 2024, reporting on its fiscal year ending December 31, 2023. The company, previously known as MYnd Ana
Emmaus Life Sciences Changes Fiscal Year End — 8-K · May 28, 2024 Risk: low
Emmaus Life Sciences, Inc. filed an 8-K on May 28, 2024, reporting a change in its fiscal year end to December 31st. This change is effective as of May 23, 2024
Emmaus Life Sciences Reports New Financial Obligations and Equity Sales — 8-K · Feb 26, 2024 Risk: medium
Emmaus Life Sciences, Inc. entered into a Material Definitive Agreement and created a Direct Financial Obligation on February 21, 2024. This filing also reports

Risk Profile

Risk Assessment: Of EMMA's 23 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Emmaus Life Sciences, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: $8.601M
Net Income: -$5.541M
Cash Position: $293K

Key Executives

Dr. Y. K. Kim
Mr. David L. L. Smith

Industry Context

Emmaus Life Sciences operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry. Success is driven by innovation, clinical trial outcomes, regulatory approvals, and effective commercialization strategies. The industry faces constant pressure from evolving treatment paradigms, generic competition, and stringent regulatory oversight from bodies like the FDA.

Top Tags

financial-reporting (5) · financials (5) · 10-Q (3) · auditor-change (3) · financial-results (2) · pharmaceuticals (2) · management-change (2) · corporate-governance (2) · filing (2) · Biopharmaceutical (2)

Key Numbers

Net Revenues: $8.601M — Decreased from $13.361M in 2024, a 35.6% decline for nine months ended Sep 30, 2025
Net Loss: $5.541M — Increased from $4.705M in 2024 for nine months ended Sep 30, 2025
Cash and Cash Equivalents: $293K — As of Sep 30, 2025, down from $1.389M at Dec 31, 2024
Working Capital Deficit: $59.4M — As of Sep 30, 2025, indicating severe liquidity issues
Total Current Liabilities: $64.169M — As of Sep 30, 2025, significantly exceeding current assets
Interest Expense: $4.865M — For nine months ended Sep 30, 2025, up from $4.214M in 2024
Loss on Debt Extinguishment: $672K — For nine months ended Sep 30, 2025, contributing to other expense
Common Shares Outstanding: 63,865,571 — As of Nov 11, 2025
Net Revenues (Q2 2025): $2.817M — 47.6% decrease from $5.377M in Q2 2024
Net Revenues (H1 2025): $5.223M — 33.8% decrease from $7.883M in H1 2024
Net Loss (Q2 2025): $1.135M — Improved from $2.184M in Q2 2024
Net Loss (H1 2025): $3.465M — Improved from $6.532M in H1 2024
Net Loss Per Share (Q2 2025): $0.02 — Improved from $0.03 in Q2 2024
Net Loss Per Share (H1 2025): $0.05 — Improved from $0.10 in H1 2024
Gain on Lease Modification: $861K — Contributed to reduced net loss in H1 2025

Frequently Asked Questions

What are the latest SEC filings for Emmaus Life Sciences, INC. (EMMA)?

Emmaus Life Sciences, INC. has 26 recent SEC filings from Feb 2024 to Mar 2026, including 19 8-K, 5 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EMMA filings?

Across 26 filings, the sentiment breakdown is: 2 bearish, 24 neutral. The dominant sentiment is neutral.

Where can I find Emmaus Life Sciences, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Emmaus Life Sciences, INC. (EMMA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Emmaus Life Sciences, INC.?

Key financial highlights from Emmaus Life Sciences, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for EMMA?

The investment thesis for EMMA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Emmaus Life Sciences, INC.?

Key executives identified across Emmaus Life Sciences, INC.'s filings include Dr. Y. K. Kim, Mr. David L. L. Smith.

What are the main risk factors for Emmaus Life Sciences, INC. stock?

Of EMMA's 23 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Emmaus Life Sciences, INC.?

Forward guidance and predictions for Emmaus Life Sciences, INC. are extracted from SEC filings as they are enriched.